LGC Clinical Diagnostics and AccuGenomics Collaborate on Enhancing Cancer Testing Accuracy

LGC (London, UK), a global leader in clinical diagnostics and genomics, and AccuGenomics (Wilmington, NC, USA), a pioneer in molecular diagnostic development, have entered into a new strategic partnership to combine LGC’s expertise in quality control solutions with AccuGenomics’ advanced NGS monitoring technologies, driving innovation in clinical diagnostic tools.

The companies will focus on developing highly accurate and reliable molecular diagnostics and quality control materials, fulfilling the vital needs of precision medicine and improving patient management. Through this collaboration, LGC and AccuGenomics intend to deliver enhanced solutions for cancer NGS testing quality control. LGC’s extensive clinical genomics reference material expertise, combined with AccuGenomics’ proprietary technology, will allow laboratories across the world to integrate third party controls into their procedures, ensuring more reliable, actionable patient results from NGS-based assays. Additionally, the companies will also develop custom reference materials for NGS assay validation, supporting the evolving landscape of precision diagnostics. LGC and AccuGenomics expect this collaboration to speed up the adoption of NGS technologies in clinical laboratories across the world.

“We are delighted to partner with AccuGenomics to further our mission of providing laboratories with cutting-edge quality control solutions,” said Bharathi Anekella, Executive Vice President of LGC. “This collaboration aligns perfectly with our vision of advancing global diagnostics and supporting healthcare providers with the tools they need to deliver better patient outcomes.”

“This partnership with LGC will expand the reach of our proprietary technologies and enable more laboratories to improve the reliability of their patient testing by NGS,” added Nick Lazaridis, President of AccuGenomics. “LGC is well aligned across the diagnostic, therapeutic and pharmaceutical sectors as a strategic distribution partner. Our focus is on improving the accuracy and sensitivity of challenging NGS applications like liquid biopsy detection for MRD; this partnership with LGC will accelerate the adoption of Accukit ctDNA MRD IS, and Accukit Myeloid DNA IS. Together, we can contribute to the development of more precise life-saving diagnostic tools that support personalized medicine, leading to more accurate clinical NGS tests.”

Related Links:
LGC 
AccuGenomics

Visit expo >

New

Gold Member

ZIKA Virus Test

ZIKA ELISA IgG

New

Gold Member

Pharmacogenetics Panel

VeriDose Core Panel v2.0

New

H. pylori Test

STANDARD Q H. pylori Ab Test

New

Moxifloxacin Resistance Assay

Allplex MG & MoxiR Assay